NASDAQ:BPTS Biophytis (BPTS) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free BPTS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$8.22▼$19.6052-Week Range N/AVolume18,500 shsAverage Volume7,291 shsMarket Capitalization$2.89 millionP/E RatioN/ADividend YieldN/APrice Target$600.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestTrends Get Biophytis alerts: Email Address Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Biophytis Stock (NASDAQ:BPTS)Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Read More Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. BPTS Stock News HeadlinesApril 9, 2024 | theglobeandmail.comBiotech Catches Major Premarket Bid Following Financial ResultsApril 9, 2024 | finance.yahoo.comWhy Is Penny Stock Biophytis Trading Higher On Tuesday?April 9, 2024 | investorplace.comWhy Is Biophytis (BPTS) Stock Up 43% Today?April 8, 2024 | finanznachrichten.deBiophytis announces its 2023 financial results -2-April 4, 2024 | finance.yahoo.comResults of the Combined General Meeting on April 2, 2024March 22, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday TradingMarch 19, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Flat in Tuesday TradingMarch 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday TradingDecember 20, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher WednesdayOctober 30, 2023 | finance.yahoo.comBiophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in BrazilOctober 27, 2023 | marketwatch.comBiophytis ADS Fall 8.5% in After Receiving Nasdaq NoticeOctober 27, 2023 | finance.yahoo.comBiophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings PanelSeptember 29, 2023 | proactiveinvestors.comBiophytis shares surge 41% following Covid partnership with France's SkyepharmaSeptember 26, 2023 | finance.yahoo.comBiophytis (BPTS) Soars 73% on Partnership With SkyepharmaSeptember 25, 2023 | benzinga.comWhy Biophytis (BPTS) Shares Are Sky-RocketingSeptember 25, 2023 | markets.businessinsider.comBiophytis Shares Surge 79% Following Covid-19 Partnership With SkyepharmaSeptember 25, 2023 | marketwatch.comBiophytis Shares Rise 41% After Partnership Deal With SkyepharmaSeptember 25, 2023 | finance.yahoo.comBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)September 25, 2023 | msn.comWhy Is Biophytis (BPTS) Stock Up 49% Today?September 25, 2023 | finance.yahoo.comBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)September 20, 2023 | finanznachrichten.deBiophytis Provides an Update on its Early Access Programs for Sarconeos in the Treatment of Severe Forms of COVID-19September 19, 2023 | finance.yahoo.comBiophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19September 14, 2023 | finance.yahoo.comBiophytis Strengthens its Management Team with the Appointment of its Chief Business OfficerSeptember 11, 2023 | finanznachrichten.deBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaSeptember 11, 2023 | finance.yahoo.comBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaSee More Headlines Receive BPTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTS CUSIPN/A CIK1768946 Webwww.biophytis.com Phone33-1-44-37-23-00FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$600.00 High Stock Price Target$600.00 Low Stock Price Target$600.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($17.29) per share Price / BookN/AMiscellaneous Outstanding Shares351,000Free Float338,000Market Cap$2.89 million OptionableNot Optionable Beta1.05 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Stanislas Veillet Ph.D. (Age 59)Chairman of the Board & CEO Comp: $374.39kMr. Nicolas Fellmann (Age 56)Chief Financial Officer Mr. Waly Dioh Ph.D. (Age 55)Chief Clinical Operating Officer Dr. Pierre J. Dilda Ph.D. (Age 54)Chief Scientific Officer Dr. Rene Lafont (Age 78)Scientific Advisor & Member of Scientific Advisory Board Dr. Rob van Maanen FFPM (Age 53)M.B.A., M.D., Chief Medical Officer Mr. Edouard Bieth (Age 44)Chief Business Officer Ms. Chiara BaccelliChief Pharmaceutical Operations Officer & Quality Assurance DirectorMs. _ TeylanFinancial ControllerMore ExecutivesKey CompetitorsVaxxinityNASDAQ:VAXXGalera TherapeuticsNASDAQ:GRTXMonopar TherapeuticsNASDAQ:MNPRMoleculin BiotechNASDAQ:MBRXKintara TherapeuticsNASDAQ:KTRAView All Competitors BPTS Stock Analysis - Frequently Asked Questions Should I buy or sell Biophytis stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTS shares. View BPTS analyst ratings or view top-rated stocks. What is Biophytis' stock price target for 2024? 1 analysts have issued 1 year price targets for Biophytis' shares. Their BPTS share price targets range from $600.00 to $600.00. On average, they anticipate the company's stock price to reach $600.00 in the next year. View analysts price targets for BPTS or view top-rated stocks among Wall Street analysts. When did Biophytis' stock split? Biophytis shares reverse split before market open on Tuesday, April 23rd 2024. The 1-40 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Biophytis IPO? Biophytis (BPTS) raised $20 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,200,000 shares at a price of $15.00-$18.00 per share. H.C. Wainwright served as the underwriter for the IPO. How do I buy shares of Biophytis? Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPTS) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.